Johnson & Johnson’s Tremfya (guselkumab) demonstrated significant clinical remission and endoscopic response in patients with Crohn’s disease in the Phase 3 GRAVITI study. The drug achieved over three times the clinical remission rate compared to placebo, indicating its potential as a treatment option for this debilitating condition.
Johnson & Johnson’s Tremfya (guselkumab) demonstrated significant clinical remission and endoscopic response in patients with Crohn’s disease in the Phase 3 GRAVITI study. The drug achieved over three times the clinical remission rate compared to placebo, indicating its potential as a treatment option for this debilitating condition.
